HoneyNaps has developed a next-generation wireless polysomnography system that replaces the more than 24 wired sensors commonly associated with comprehensive laboratory sleep testing with four compact skin-mounted sensor modules. The Head Sensor, Chest Sensor, Body Sensor and Leg Sensor are designed collectively to capture electroencephalography, electrooculography, electrocardiography, electromyography, respiratory airflow, oxygen saturation, body position and physical activity. Data can then be integrated with HoneyNaps’ SOMNUM artificial-intelligence software for automated analysis of sleep stages, respiratory events, arousals and periodic limb movements.
The concept directly targets one of the awkward realities of polysomnography: the test used to diagnose complex sleep disorders can itself make normal sleep difficult. Conventional laboratory PSG requires numerous electrodes, respiratory sensors and other leads positioned around the head and body, often while the patient sleeps overnight in an unfamiliar clinical environment. HoneyNaps argues that reducing cabling could improve comfort, simplify setup and eventually support broader hospital, remote-monitoring and home applications. The company’s September 4 release, however, does not state that the new Wireless PSG hardware itself has received FDA clearance, so it should not be described as an FDA-cleared four-patch system.
What do the four HoneyNaps patches actually measure?
The Head Sensor is intended to capture signals related to brain activity, eye movements and associated sleep-state measurements, while the other modules distribute cardiac, muscular, respiratory, oxygen and motion sensing across the chest, body and legs. HoneyNaps says the architecture collectively captures the principal physiological channels required for comprehensive polysomnography without conventional cabling.
Established polysomnography typically includes EEG to determine sleep stage, EOG to identify eye movements, chin or other EMG signals, airflow, oxygen saturation, respiratory effort and heart rate or ECG. These channels allow a sleep laboratory to determine whether the patient is asleep, what stage of sleep they are in, whether breathing has stopped or become restricted, whether oxygen falls and whether abnormal movements are occurring. Technical guidance has long treated this multi-channel capability as what separates full PSG from simpler home respiratory testing.
HoneyNaps is therefore not trying merely to build a smaller pulse oximeter. Its engineering proposition is to compress the multi-sensor information required for a full sleep study into a much less cumbersome wearable arrangement.
Why does reducing wires matter if conventional polysomnography already works?
Diagnostic accuracy is only one part of a successful sleep study. Technicians must correctly place many sensors, prevent electrodes from becoming detached and manage cables throughout the night. Patients can find the arrangement uncomfortable, and movement can create signal artifacts or dislodge leads. A study conducted in an unfamiliar laboratory under extensive wiring may also differ from the patient’s ordinary night at home.
A simpler patch architecture could reduce preparation time and make repeat studies easier while allowing greater freedom of movement during sleep. It could be particularly valuable for children, older adults or patients who struggle to tolerate conventional laboratory instrumentation.
The benefit cannot be assumed merely from fewer components, however. Consolidation only works if wireless patches produce signal quality sufficiently stable to support clinical scoring. EEG and respiratory signals can be vulnerable to motion artifact, poor skin contact and electrical noise, meaning HoneyNaps will need validation showing that comfort has not been purchased at the expense of diagnostic fidelity.
What engineering changes has HoneyNaps built into the wireless system?
The company says its patches use a six-layer flexible printed circuit board, integrated analog-to-digital conversion and sensor architecture, wireless noise-reduction techniques, electrostatic-discharge protection and a low-power design. These engineering features are intended to preserve signal quality over extended monitoring while keeping the system wearable.
Wireless medical monitoring introduces challenges that conventional tethered equipment partly avoids. Battery capacity must last through the required recording period, synchronization between modules must remain precise, and signal transmission must be reliable despite body movement and changing positions. Data loss from one patch could compromise interpretation of an entire respiratory event if the system cannot reconcile the missing channel.
HoneyNaps has not yet released a peer-reviewed head-to-head validation study showing agreement between its four-patch platform and conventional full PSG across a large clinical population. That evidence would be particularly important before the system is used to replace standard laboratory instrumentation rather than simply complement it.
Where does SOMNUM fit into the new wireless PSG platform?
SOMNUM is HoneyNaps’ automated sleep-analysis software. The company says it analyzes sleep stages, apnea and other respiratory events, arousals and periodic limb movements, reducing some of the manual scoring work ordinarily performed after a sleep study. The new wireless hardware is being designed to send its physiological data into that software environment.
Unlike the newly announced hardware, SOMNUM does have an FDA regulatory history. FDA records show that the current SOMNUM software received 510(k) clearance under K253390 on June 27, 2026 as Class II automatic event-detection software for polysomnography with electroencephalography. HoneyNaps also had an earlier SOMNUM version cleared in 2023.
This distinction matters editorially and clinically. An FDA-cleared analysis program does not automatically confer clearance on every new sensor system connected to it. HoneyNaps will need to establish the regulatory pathway applicable to the Wireless PSG hardware and any integrated claims before the complete four-patch platform can be described as authorized for U.S. clinical use.
Could four patches eventually bring full polysomnography into the home?
That is one of HoneyNaps’ stated ambitions, but it should be treated as a future application rather than an established capability. Many home sleep apnea tests intentionally record fewer physiological channels than laboratory PSG because simplicity makes unattended testing possible. They can be effective in appropriately selected patients, but they do not provide the same neurological and sleep-stage information as full polysomnography.
A wireless system capable of obtaining reliable EEG, EOG, EMG, respiratory, cardiac, oxygen and movement data at home could narrow that gap. It might allow patients to sleep in their ordinary environment while generating richer information than standard home apnea testing. Such a system could also support repeated monitoring rather than relying on a single laboratory night.
The operational challenge is considerable. Patients or caregivers would need to place sensors correctly without a sleep technologist physically present, devices would need to detect poor signal quality early enough to correct it, and clinicians would need confidence that unattended data remain diagnostically reliable.
Why could AI become particularly valuable as sleep testing moves outside specialist laboratories?
A full overnight polysomnogram can contain hours of multichannel physiological information divided into short epochs that must be classified by sleep stage and inspected for respiratory events, arousals and limb movements. Automated software can perform much of that preliminary scoring and direct clinicians toward segments requiring attention.
The value increases if testing volume grows. Moving PSG from specialist sleep laboratories toward distributed hospital networks or home monitoring could create more data than existing technologists can manually score efficiently. AI-assisted analysis therefore becomes an operational component of scaling rather than simply a novelty added to the diagnostic test.
Automation also creates risk. Sleep scoring can be complicated by unusual physiology, medications, neurological disease, signal artifact and mixed respiratory events. FDA-cleared automatic event-detection software remains a clinical aid, not an invitation to remove qualified physician oversight.
How could the new platform affect sleep apnea diagnosis?
Obstructive sleep apnea is one of the most common reasons for sleep testing, and access to diagnosis can be limited by laboratory capacity, waiting times and patient reluctance to undergo an overnight wired study. A comfortable multi-channel system that simplifies setup could theoretically increase testing throughput and reduce barriers for some patients.
Better comfort could also improve the representativeness of a recording if patients sleep more naturally. On the other hand, even a comfortable test is only useful if it accurately identifies airflow limitation, respiratory effort, sleep time and oxygen changes needed to calculate clinically meaningful apnea-hypopnea measures.
For this reason, the most important future dataset for HoneyNaps would not simply show that patients prefer four patches. It would demonstrate close agreement with conventional clinical polysomnography for sleep staging, apnea-hypopnea index, oxygen desaturation, arousal detection and limb-movement scoring across a broad spectrum of sleep disorders.
Is the HoneyNaps Wireless PSG commercially available as an FDA-cleared U.S. device?
The September announcement says HoneyNaps has developed the platform and discusses potential hospital, home and remote-monitoring applications. It does not identify an FDA 510(k), De Novo authorization or other U.S. clearance for the newly developed Wireless PSG hardware. Therefore, the safe description is that HoneyNaps has unveiled or developed the system, not that the FDA has authorized it for clinical diagnosis.
The regulatory position of SOMNUM is different. FDA records independently confirm clearance of the software, but that software clearance should be stated separately from the status of the new patches.
This is precisely the sort of distinction that will matter as medical AI increasingly becomes integrated with new sensing hardware. A company may have a cleared algorithm, an investigational sensor and a future integrated product under one brand ecosystem, yet each component can occupy a different regulatory position.
What should sleep clinics watch as HoneyNaps develops the system further?
Clinical validation should come first. Sleep laboratories will want to know the failure rate of individual patches, setup time, overnight battery performance, data-loss frequency and agreement with conventional PSG. They will also want evidence that the system performs across different body types, ages, sleeping positions and disease severities rather than only in healthy volunteers or controlled engineering tests.
Regulatory status will be the second major milestone. A formal U.S. clearance for the hardware or integrated platform would clarify exactly which diagnostic claims HoneyNaps can make and whether the system can serve as a direct alternative to established PSG equipment.
The company has produced an appealing engineering concept: four compact patches collecting the physiological information that normally requires an intimidating web of sensors and wires, connected to already FDA-cleared AI analysis software. The remaining challenge is the one that matters most in diagnostics. HoneyNaps now has to demonstrate that substantially simplifying the patient experience does not simplify away any of the clinical information physicians depend on to diagnose sleep disorders correctly.
